[HTML][HTML] Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
[HTML][HTML] Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - ncbi.nlm.nih.gov
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - pure.johnshopkins.edu
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
D Focosi, A Casadevall, M Franchini… - Viruses (1999 …, 2024 - search.ebscohost.com
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - pubmed.ncbi.nlm.nih.gov
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - go.gale.com
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - europepmc.org
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
D Focosi, A Casadevall, M Franchini, F Maggi - Viruses, 2024 - europepmc.org
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …